Ezeife DA - Search Results

1

Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System.

Makarem M, Ezeife DA, Smith AC, Li JJN, Law JH, Tsao MS, Leighl NB. Makarem M, et al. Among authors: ezeife da. Curr Oncol. 2021 Aug 25;28(5):3268-3279. doi: 10.3390/curroncol28050284. Curr Oncol. 2021. PMID: 34449580 Free PMC article.

2

Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?

Cheng S, McDonald EJ, Cheung MC, Arciero VS, Qureshi M, Jiang D, Ezeife D, Sabharwal M, Chambers A, Han D, Leighl N, Sabarre KA, Chan KKW. Cheng S, et al. J Clin Oncol. 2017 Aug 20;35(24):2764-2771. doi: 10.1200/JCO.2016.71.6894. Epub 2017 Jun 2. J Clin Oncol. 2017. PMID: 28574778

3

Personalized medicine for non-small cell lung cancer: where are we now and where can we go?

Ezeife DA, Leighl NB. Ezeife DA, et al. Expert Rev Respir Med. 2018 Feb;12(2):81-82. doi: 10.1080/17476348.2018.1411805. Epub 2017 Dec 5. Expert Rev Respir Med. 2018. PMID: 29187004 No abstract available.

4

Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.

Ezeife DA, Kirk V, Chew DS, Nixon NA, Lee R, Le LW, Chan KK, Leighl NB. Ezeife DA, et al. Lung Cancer. 2018 Nov;125:1-7. doi: 10.1016/j.lungcan.2018.08.024. Epub 2018 Aug 30. Lung Cancer. 2018. PMID: 30429004

5

Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.

Ezeife DA, Melosky B, Tudor R, Lin S, Lau A, Panzarella T, Leighl NB. Ezeife DA, et al. Curr Oncol. 2018 Oct;25(5):e385-e390. doi: 10.3747/co.25.3914. Epub 2018 Oct 31. Curr Oncol. 2018. PMID: 30464688 Free PMC article.

6

Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System.

Ezeife DA, Morganstein BJ, Lau S, Law JH, Le LW, Bredle J, Cella D, Doherty MK, Bradbury P, Liu G, Sacher A, Shepherd FA, Leighl NB. Ezeife DA, et al. Clin Lung Cancer. 2019 Jul;20(4):231-236. doi: 10.1016/j.cllc.2018.12.010. Epub 2018 Dec 22. Clin Lung Cancer. 2019. PMID: 30797721

7

Real-World Adherence to Guideline-Recommended Treatment for Small Cell Lung Cancer.

Elegbede AA, Gibson AJ, Fu H, Dean ML, Ezeife DA, Lau H, Cheung WY, Bebb DG. Elegbede AA, et al. Among authors: ezeife da. Am J Clin Oncol. 2020 Apr;43(4):236-242. doi: 10.1097/COC.0000000000000657. Am J Clin Oncol. 2020. PMID: 31842113

8

Value assessment of oncology drugs using a weighted criterion-based approach.

Ezeife DA, Dionne F, Fares AF, Cusano ELR, Fazelzad R, Ng W, Husereau D, Ali F, Sit C, Stein B, Law JH, Le L, Ellis PM, Berry S, Peacock S, Mitton C, Earle CC, Chan KKW, Leighl NB. Ezeife DA, et al. Cancer. 2020 Apr 1;126(7):1530-1540. doi: 10.1002/cncr.32639. Epub 2019 Dec 20. Cancer. 2020. PMID: 31860138 Free article.

9

An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access.

Leighl NB, Nirmalakumar S, Ezeife DA, Gyawali B. Leighl NB, et al. Among authors: ezeife da. Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-12. doi: 10.1200/EDBK_100028. Am Soc Clin Oncol Educ Book. 2021. PMID: 33956494 Free article.

10

The financial impact of cancer care on renal cancer patients.

Ezeife DA, Morganstein BJ, Yip S, Ryan M, Law JH, Guan AY, Le LW, Hansen AR, Sacher A, Bjarnason GA, Doherty MK, Leighl NB. Ezeife DA, et al. Can J Urol. 2021 Aug;28(4):10762-10767. Can J Urol. 2021. PMID: 34378512

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page